October 20th, 2026Tezepelumab sustains EoE remission through 52 weeks Tezepelumab produced histologic remission in up to 68.9% of patients aged 12+ with EoE vs 3.5% with placebo at week 24, sustained to week 52.Read more
October 19th, 2026Mirikizumab meets 1-year remission end point in pediatric UCIn phase 3 SHINE-2, 50% of mirikizumab induction responders aged 6 to 17 with moderate to severe UC were in clinical remission at week 52.Read more
November 4th, 2026November 2026 preview: 4 FDA decisions to watch in pediatric careFind out the 4 FDA decisions to watch in November 2026 for pediatric care.Read more
November 4th, 2026Cenobamate sNDAs seek PGTC and pediatric focal seizure indicationsCenobamate sNDAs target PGTC seizures in patients ≥12 years and pediatric focal seizures; phase 3 PGTC data showed a 71.9% median reduction.Read more
November 3rd, 2026FDA approves Lupin's generic amifampridine for LEMSFDA approved Lupin's generic of Firdapse for LEMS in patients 6 years and older, but a patent settlement delays US marketing until at least 2035.Read more
November 2nd, 2026Clinical trial news in pediatrics: October 2026A recap of the top pediatric clinical trial results and pipeline data readouts during October 2026.Read more
November 2nd, 2026FDA news in pediatrics: October 2026A recap of the top FDA approvals, regulatory decisions, and pipeline updates affecting pediatric care during October 2026.Read more
October 26th, 2026Zilurgisertib reduces HO volume in children aged 6 to 11 with FOPIn PROGRESS Cohort 2, zilurgisertib reduced total HO volume vs placebo at 24 weeks in children aged 6 to 11 with FOP, with no new HO lesions.Read more